Cariprazine test for teens with schizophrenia
Treatments studied
Part of Mental health clinical trials.
This trial tests whether cariprazine works and is safe for teens aged 13 to 17 with schizophrenia. It may help if your symptoms are still moderate to severe despite current care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 13 and 17 years old
- A clinician confirms you have schizophrenia using a structured interview (K-SADS-PL)
- Your symptom ratings at screening and start of the study are high enough (PANSS overall and key symptom areas)
- Your overall illness severity is at least “moderately ill” at both screening and baseline (CGI-S)
- You do not have bipolar disorder, schizoaffective disorder, or other related psychotic diagnoses
- You do not have an intellectual disability (IQ under 70)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine, KarXT, can safely and effectively treat schizophrenia in adolescents. It may help teenagers who have active symptoms like hallucinations or disorganized thinking.
This study tests whether a new medication called aticaprant is safe and well-tolerated when added to your current antipsychotic medication for schizophrenia. The goal is to see if it could help improve symptoms without causing serious side effects.
This trial tests a monthly injection of cariprazine (a medication for mental health conditions) in people who could benefit from it. It aims to see if the shot is safe, tolerable, and effective compared to taking pills every day.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
This study tests a new extended-release injection for schizophrenia, comparing it to the existing drug Vraylar. It's for people who are currently stable on their antipsychotic medication and have tolerated oral cariprazine before.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.